Shots: Bridge to receive $50.66M as up front and near-term payments, up to $1.23B based on development, regulatory, and commercial milestones and royalties on sales The focus of the collaboration […]readmore
Tags : Agreement
Shots: The companies will develop a pipeline of products used for diagnosing and assessing the risks of thyroid cancer, leveraging Interpace’s ThyGeNEXT and ThyraMIR assays combining with Helomics’ patient-derived tumor […]readmore
Shots: Frequency to receive $80M up front, up to $545M as development & commercial milestone and royalties on sales in the licensed territory. Frequency will hold the rights to develop […]readmore
Shots: Sosei Heptares to receive $26M as up front and near-term payment, up to $1B as research, development and commercialization milestones and royalties on sales. Genentech to get exclusive WW […]readmore
Shots: Genentech & Convelo collaborate to discover and develop remyelination therapies for patients with neurological disorders including multiple sclerosis Convelo to receive up front and research support from Genentech. Genentech […]readmore
Shots: Skyhawk to receive up front, more than $2B as option fee & milestones, royalties on sales and will utilize its SkySTAR technology platform to discover and develop RNA splicing […]readmore
Shots: MacroGenics to receive $15M up front, up to $135M as development & regulatory milestones and royalties on sales in Greater China. I-Mab to get development & commercialization rights for […]readmore
Shots: Celsius to receive payments and milestones based on the use of biomarkers identified, holding the rights to integrate the data generated from the study into its database of patient […]readmore
Shots: Novartis will provide TNO155 at no cost while Mirati will sponsor the clinical study evaluating the combination therapy for solid tumors harboring KRAS G12C mutations and the companies will […]readmore
Shots: Nosopharm and Evotec collaborated to advance Nosopharm’s NOSO-502 to clinical stage and to develop second-generation Odilorhabdin (ODLs) for hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP), under the name NOSO-2G The […]readmore